DE69941300D1 - Fahren und verwendungen - Google Patents

Fahren und verwendungen

Info

Publication number
DE69941300D1
DE69941300D1 DE69941300T DE69941300T DE69941300D1 DE 69941300 D1 DE69941300 D1 DE 69941300D1 DE 69941300 T DE69941300 T DE 69941300T DE 69941300 T DE69941300 T DE 69941300T DE 69941300 D1 DE69941300 D1 DE 69941300D1
Authority
DE
Germany
Prior art keywords
gene
parkin
exons
deletion
amplifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941300T
Other languages
English (en)
Inventor
Alexis Brice
Christophe Lucking
Nacer Eddine Abbas
Patrice Denefle
Sylvain Ricard
Sandrine Bouley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Aventis Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE69941300D1 publication Critical patent/DE69941300D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69941300T 1998-11-19 1999-11-18 Fahren und verwendungen Expired - Lifetime DE69941300D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (1)

Publication Number Publication Date
DE69941300D1 true DE69941300D1 (de) 2009-10-01

Family

ID=27253486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941300T Expired - Lifetime DE69941300D1 (de) 1998-11-19 1999-11-18 Fahren und verwendungen

Country Status (15)

Country Link
US (3) US8835618B2 (de)
EP (5) EP2128257A3 (de)
JP (1) JP5424519B2 (de)
AT (1) ATE440138T1 (de)
AU (1) AU778281B2 (de)
CA (1) CA2351567C (de)
CY (1) CY1110535T1 (de)
DE (1) DE69941300D1 (de)
DK (1) DK1131424T3 (de)
ES (1) ES2330281T3 (de)
IL (3) IL142755A0 (de)
NO (5) NO330896B1 (de)
NZ (1) NZ512313A (de)
PT (1) PT1131424E (de)
WO (1) WO2000031253A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (de) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenes Tiermodel für neurodegenerative Erkrankungen
US20040248092A1 (en) * 2000-05-26 2004-12-09 Vance Jeffrey M Methods of screening for parkinsons's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
WO2021237158A1 (en) * 2020-05-21 2021-11-25 Nysnobio Gt, Llc Gene therapy delivery of parkin mutants having increased activity to treat parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672753B1 (de) * 1993-10-05 2008-01-02 Asahi Glass Company Ltd. Vektor zur vielfachklonierung, expressionsvektor und herstellung von fremdprotein mit expressionsvektor
WO1996039535A1 (en) 1995-06-06 1996-12-12 Jan Vijg Method of and apparatus for diagnostic dna testing
US6716621B1 (en) 1998-02-09 2004-04-06 Boehringer Ingelheim International Gmbh Isolated DNA or gene responsible for Parkinson's disease
CA2872581C (fr) * 1998-11-19 2018-04-10 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
EP1131424B1 (de) 2009-08-19
CY1110535T1 (el) 2015-04-29
EP2311954A1 (de) 2011-04-20
JP2002536961A (ja) 2002-11-05
PT1131424E (pt) 2009-10-23
NO20012342D0 (no) 2001-05-11
DK1131424T3 (da) 2009-11-23
EP1131424A2 (de) 2001-09-12
WO2000031253A2 (fr) 2000-06-02
IL142755A0 (en) 2002-03-10
CA2351567C (fr) 2016-01-12
IL142755A (en) 2009-08-03
EP2128257A2 (de) 2009-12-02
NZ512313A (en) 2003-12-19
US9540693B2 (en) 2017-01-10
NO332173B1 (no) 2012-07-16
NO330896B1 (no) 2011-08-08
NO20012342L (no) 2001-07-18
NO20110580L (no) 2001-07-18
ES2330281T3 (es) 2009-12-07
NO332174B1 (no) 2012-07-16
ATE440138T1 (de) 2009-09-15
WO2000031253A3 (fr) 2000-09-28
CA2351567A1 (fr) 2000-06-02
EP2345722A1 (de) 2011-07-20
NO20110582L (no) 2001-07-18
EP2305816A1 (de) 2011-04-06
NO20110578L (no) 2001-07-18
US8835618B2 (en) 2014-09-16
US20150074836A1 (en) 2015-03-12
NO333907B1 (no) 2013-10-14
AU778281B2 (en) 2004-11-25
JP5424519B2 (ja) 2014-02-26
US20120064598A1 (en) 2012-03-15
NO333906B1 (no) 2013-10-14
US20170183736A1 (en) 2017-06-29
NO20110577L (no) 2001-07-18
IL187652A (en) 2010-02-17
AU1276900A (en) 2000-06-13
EP2128257A3 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
NO20110577L (no) Mutasjon av parkingen, preparater, fremgangsmater og anvendelser
Manchenko Handbook of detection of enzymes on electrophoretic gels
GB2376018A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human placenta
ATE391175T1 (de) Multidrug resistenz gen
EP1151140A4 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
ATE513851T1 (de) Menschliches gen zur fruchtbarkeit entscheidend
EP0128018A3 (en) Molecular genetic probe, and method of forming same, assay technique and kit using said molecular genetic probe
Cao et al. Association of matrix metalloproteinase‐1 promoter polymorphism with generalized aggressive periodontitis in a Chinese population
AU614489B2 (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
ATE139260T1 (de) Diagnostische gene zum nachweis von toxoplasmose
DE69809561D1 (de) Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
Broome et al. Non‐invasive transgenic mouse genotyping using stool analysis
ATE455562T1 (de) Endothelzellspezifität zeigende promotoren und verfahren zu deren verwendung
ATE308615T1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
ATE373095T1 (de) Mutierte muskelspezifische enhancer
ATE315104T1 (de) Glaukom diagnose und behandlung
DE60038029D1 (de) Methoden und reagenzien zur in situ amplifizierung
WO2002086113A3 (en) Enzyme and snp marker for disease
Silverton CRIME AND THE SCHIZOPHRENIA SPECTRUM: A STUDY OF TWO DANISH COHORTS.
EP1446485A4 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
MXPA02004825A (es) Genes especificamente expresados en celulas dendriticas humanas.
Christensen et al. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin
Ledford CRISPR hack transform s cells into data recorders
Hecht Sequence analysis of Pmel17 as candidate gene for causing rat-tail syndrome in cattle
Basset et al. Identification of three Sorex species with microsatellite markers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition